Spectrum Pharma (SPPI) Announces Presentation of Encouraging Poziotinib Preclinical Data at 17th IASLC World Conference
- Consumer staples stocks help Wall St. pare some losses
- BAT Reaches Deal to Acquire Reynolds American (RAI) for $49 Billion
- Verizon Communications (VZ) May Acquire Big Cable Company - NYP (CHTR) (CMCSA)
- Citron Research Negative on Lannett (LCI); Sees Shares at 'Zero' Over Long Term
- Einhorn's Greenlight Mentions Caterpillar (CAT) Short in Q4 Letter; Doesn't See Disney (DIS) Buying Netflix (NFLX)
Get the Pulse of the Market with StreetInsider.com's Pulse Picks. Get your Free Trial here.
Spectrum Pharmaceuticals (Nasdaq: SPPI) announced that scientists from MD Anderson Cancer Center will be presenting data from a preclinical study evaluating poziotinib in lung cancer at the 17th International Association for the Study of Lung Cancer (IASLC) World Conference on Lung Cancer taking place in Vienna, Austria, December 4-7, 2016.
“Poziotinib has shown promising efficacy in preclinical models of non-small cell lung cancer (NSCLC) with exon 20 insertion mutations,” said John Heymach, MD, PhD, Chairman, Professor, and David Bruton Junior Chair in Cancer Research, Department of Thoracic/Head and Neck Medical Oncology, The University of Texas MD Anderson Cancer Center. “Tumors with these mutations have generally not been responsive to approved EGFR inhibitors, and there is an unmet need for better therapies for these patients. Computational modeling suggests that poziotinib may overcome steric hindrance of the drug binding pocket induced by the exon 20 insertion mutations. Based on these results, we are in the process of initiating a Phase 2 study in lung cancer that we plan to start in the near future.”
“Poziotinib has already shown promising data in breast cancer, and we are excited that it may now have application in lung cancer as well," said Rajesh C. Shrotriya, MD, Chairman and Chief Executive Officer of Spectrum Pharmaceuticals. “Lung cancer is the leading cause of cancer deaths in the world. Due to the mutations in the genes, lung cancer often becomes unresponsive to treatments. Patients who have exon 20 insertion mutations have few options, if any. We look forward to working closely with MD Anderson Cancer Center to continue development of this drug in this area of unmet medical need.”
17th IASLC World Conference on Lung Cancer
|Poziotinib overcomes de novo resistance of EGFR exon 20 insertion mutations in NSCLC|
Oral Presentation Schedule:
|December 7, 2016 Session “Novel Strategies in Targeted Therapies”|
Poziotinib is a novel, oral pan-HER inhibitor that irreversibly blocks signaling through the Epidermal Growth Factor Receptor (EGFR, HER) Family of tyrosine-kinase receptors, including HER1 (erbB1; EGFR), HER2 (erbB2), and HER4 (erbB4), and importantly, also HER receptor mutations; this, in turn, leads to the inhibition of the proliferation of tumor cells that overexpress these receptors. Mutations or overexpression/amplification of EGFR family receptors have been associated with a number of different cancers, including non-small cell lung cancer (NSCLC), breast cancer, and gastric cancer.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Biogen (BIIB), Forward Pharma (FWP) Enter Settlement and License Agreement; Biogen to Pay $1.25B, Royalties
- Corbus Pharma (CRBP) Receives UE Orphan Designation for JBT-101 for Treatment of Systemic Sclerosis
- ExxonMobil (XOM) to Acquire Assets in Permian Basin for $5.6B in Shares Plus $1B in Contingent Cash Payments
Create E-mail Alert Related CategoriesCorporate News, FDA
Related EntitiesDefinitive Agreement
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!